National Guideline Clearinghouse | American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

National Guideline Clearinghouse | American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.: "Guideline Title
American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.

Bibliographic Source(s)
Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH. American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. Alexandria (VA): American Society of Clinical Oncology (ASCO); 2011. 17 p. [77 references]

Guideline Status

This is the current release of the guideline.

This guideline updates a previous version: Hillner BE, Ingle JN, Chlebowski RT, Gralow J, Yee GC, Janjan NA, Cauley JA, Blumenstein BA, Albain KS, Lipton A, Brown S. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003 Nov 1;21(21):4042-57.

full-text:
National Guideline Clearinghouse | American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer.: "Guideline Title
American Society of Clinical Oncology clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. - Enviado mediante la barra Google"